It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...
Hosted on MSN
This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First?
The global cell therapy market was valued at $5.88 billion in 2024 and is on track to hit $44.39 billion by 2034, expanding at a striking 22.69% CAGR. Researchers credit this explosive growth to ...
In this article, we will take a look at the 9 Best Gene-Editing Stocks to Buy According to Hedge Funds. Genetic manipulation – or gene editing – is a concept that describes altering the genetic ...
Sarepta Therapeutics Inc (NASDAQ:SRPT) is one of the best gene therapy stocks to buy in 2026. Sarepta’s Q1 2026 report, released on May 6, showed that both earnings and revenue surpassed analysts’ ...
Beam Therapeutics Inc (NASDAQ:BEAM) is one of the best gene therapy stocks to buy in 2026. The stock is up roughly 27% in the past six months and soared more than 60% in the past year. The Street ...
While healthcare stocks have underperformed broader equities in recent years, there are still highly attractive companies in the sector worth consideration. However, other fairly ...
Gene therapy and gene editing are marvels of modern biotechnology, providing revolutionary techniques for fixing genetic abnormalities. Gene therapy introduces functional genetic material to treat ...
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, RBC Capital raised its price target for CRISPR Therapeutics AG (NASDAQ:CRSP ...
In late 2023/early 2024, CRISPR achieved a breakthrough in medical science after securing approval for Casgevy (exa-cel) across several countries, including the United States and Europe. This marked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results